ArticleArchives of virology2026
Virtual screening, molecular dynamics simulations, and antiviral evaluation of Ocimum basilicum phytoconstituents against Japanese encephalitis virus.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial Expression of Concern: Antiviral and neuroprotective activity of diallyl disulfide in Japanese encephalitis virus‑challenged SH‑SY5Y cells: a post‑treatment approach for greater specificity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In conventional medicinal systems, Ocimum basilicum (OB) is known to be effective against viral infections. A thorough screening of OB's phytoconstituents against Japanese encephalitis virus (JEV) in an in silico and in vitro model has not been documented. Therefore, we used Schrödinger software to do a virtual screening and molecular dynamics simulation (MDS) (100 ns) on 265 phytocompounds from OB against the envelope (E) protein (PDB ID: 3P54) of JEV. Chicoric acid (CA), rutin, and salvianolic acid A (SAA) complexes with the E protein showed outstanding docking scores of -9.136, -9.135, and - 11.838 (kcal/mol), which were all higher than that obtained with the reference compound mycophenolate (-4.481) (kcal/mol). MDS analysis revealed that these compounds, especially CA and rutin, showed comparatively strong stability in the binding pocket of the protein. CA and rutin also exhibited lower binding free energy with this protein than the standard. Moreover, principal component and free energy landscape analysis highlighted the antiviral potential of these compounds against JEV. In vitro experiments demonstrated the antiviral potential of CA and rutin at the early stage of the viral life cycle. These drugs also reduced the levels of proinflammatory cytokines (TNF-α and IL-6) and reactive oxygen species in JEV-infected cells. This study provides insight into the therapeutic potential of CA and rutin as novel drugs against JEV. Additional study is needed to validate their antiviral and neuroprotective activity in an in vivo model of JE.
Indexed as
Identifiers
41511571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.